Press Center
Get an overview of Priothera’s recent news articles, and keep up-to-date with our ongoing work and results.
If you are a professional member of the media and would like to find out more about Priothera, please contact info@priothera.com.
Patient Voice 2026
Throughout Septembre Rouge 2026, Priothera SAS invited Carolina, an AML patient advocate, to share her story in a four-part video series.
From the shock of diagnosis and the journey through stem cell transplantation to life after transplant and her hopes for the future, Carolina speaks openly about what it means to live with AML — and about the challenges that remain after transplantation.
Her story gives a voice to many patients who are waiting for more effective maintenance treatments to help prevent relapse and improve long-term outcomes — and echoes Priothera’s commitment to addressing this unmet need.
Watch the four videos:
1. The day everything changed
2. The donor who gave me a second chance
3. Life after transplant
4. My wish for innovative maintenance treatment
Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients
Priothera Receives FDA clearance of Investigational New Drug (IND)
Priothera to present an abstract at the TANDEM Meetings / Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR – April 23-26 2022
Priothera Receives First Regulatory Approvals to Start a Global Pivotal Study with Mocravimod in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Priothera Receives R&D Innovation Loan from Bpifrance
